NM8074 add-on for Soliris-treated PNH symptoms
Treatments studied
Part of Blood & lymphatic clinical trials.
This Phase 2 trial studies NM8074 in people with paroxysmal nocturnal hemoglobinuria (PNH) who are already taking Soliris. It aims to improve PNH control by targeting the disease while you stay on your current Soliris treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and can sign consent and follow all study visits
- You have confirmed PNH from blood test results (flow cytometry) showing a small “clone” size of about 5%
- In the last 3 months, you had at least one PNH-related problem such as fatigue, dark urine, anemia, shortness of breath, pain, blood clots, or needed red-blood-cell transfusions
- You have been on Soliris for at least 3 months, and your LDH lab result is high (at least 1.5 times normal)
- Your blood counts and organs are healthy enough for study (platelets, neutrophils, kidneys, and liver labs must be above set thresholds)
- You have required meningococcal vaccine documentation, and (if able to have children) you agree to reliable birth control and take a negative pregnancy test
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, XH-S003, for people with paroxysmal nocturnal hemoglobinuria (PNH) who have not tried complement inhibitors before. The goal is to see if it can help manage symptoms like low red blood cells and fatigue.
This clinical trial tests an investigational drug called EA5 for people with PNH, a rare blood disease where red blood cells break down too quickly. It is for adults who either have never taken a complement inhibitor or stopped taking one recently, and who still have signs or symptoms of PNH.
This Phase 2 trial studies NM8074 in adults with paroxysmal nocturnal hemoglobinuria (PNH) whose blood counts and breakdown of red blood cells (hemolysis) are not controlled enough on Soliris. NM8074 is meant to reduce the abnormal immune “complement” activity driving the disease and its symptoms like anemia.
This Phase 2 study tests how well and how safely NM8074 works for adults with paroxysmal nocturnal hemoglobinuria (PNH) who have not recently received a similar “complement inhibitor” medicine. It may help reduce PNH-related blood cell breakdown and anemia, and it will closely monitor side effects.
This trial tests a new pill called MY008211A for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder where red blood cells are destroyed. If you have moderate anemia and high LDH (a marker of blood cell breakdown), this study may be an option.
This trial tests a new pill (MY008211A) for people with paroxysmal nocturnal hemoglobinuria (PNH) who still have low red blood cell counts (anemia) even after taking anti-C5 antibody therapy. The goal is to see if this new drug can raise hemoglobin levels and improve energy.
Hear when a new PNH - Paroxysmal Nocturnal Hemoglobinuria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.